Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies
Authors:
- Hugues Fausther-BovendoHFHugues Fausther-Bovendo
- George (Giorgi) BabuadzeGBGeorge (Giorgi) Babuadze
- Teodora IvanciucTITeodora Ivanciuc
- Birte KalveramBKBirte Kalveram
- Yue QuYQYue Qu
- Jihae ChoiJCJihae Choi
- Allison McGeerAMAllison McGeer
- Mario OstrowskiMOMario Ostrowski
- Samira MubarekaSMSamira Mubareka
- Ami PatelAPAmi Patel
- Roberto P. GarofaloRoberto P. Garofalo
- Robert KozakRKRobert Kozak
Open Access
- 5 March 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 637
Abstract
Background: Monoclonal antibodies (mAbs) are potent treatment options for infectious diseases. The rapid isolation and in vivo validation of therapeutic mAb candidates, including mAb cocktails, are essential to combat novel or rapidly mutating pathogens. The rapid selection and production of mAb candidates in sufficient amount and quality for preclinical studies are a major limiting step in the mAb development pipeline. Methods: Here, we developed a method to facilitate the screening of therapeutic mAbs in mouse models. Four conventional mAbs were transformed into single-chain variable fragments fused to the fragment crystallizable (Fc) region of a human IgG1 (scFv-IgG). These scFv-IgG were expressed individually or as a cocktail in vitro and in mice following transfection or hydrodynamic delivery of the corresponding plasmids. Results: This method induced high expression of all scFv-IgG and provided protection in two murine infection models. Conclusions: This study highlights the benefits of this approach for the rapid, low-cost screening of therapeutic mAb candidates.Keywords
Funding Information
- Canadian Institutes of Health Research (439999)
This publication has 52 references indexed in Scilit:
- Antibody drugs targeting SARS-CoV-2: Time for a rethink?Biomedicine & Pharmacotherapy, 2024
- Therapeutic antibodies and alternative formats against SARS-CoV-2Antiviral Research, 2024
- From cell factories to patients: Stability challenges in biopharmaceuticals manufacturing and administration with mitigation strategiesInternational Journal of Pharmaceutics, 2023
- FDA Approves RSV Monoclonal Antibody for Infants and Young ChildrenJAMA, 2023
- Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeuticsBiotechnology Advances, 2023
- Nirsevimab: First ApprovalDrugs, 2022
- Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic feverCell, 2021
- In Vivo Delivery of Nucleic Acid-Encoded Monoclonal AntibodiesBioDrugs, 2020
- Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodiesAntiviral Research, 2016
- Hydrodynamics‐based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene deliveryThe Journal of Gene Medicine, 2004